Navigation Links
Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
Date:3/10/2008

sco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended September 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entir
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
2. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
3. Anesiva Appoints Daniel Janney to Board of Directors
4. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
5. Anesiva Announces Completion of Common Stock Offering
6. Anesiva Raises $45 Million in Common Stock Offering
7. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
8. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... Research and Markets  has announced the addition ... Strategic Business Report" report to their offering. ... Fuel Cells (SOFCs) in US$ Thousands. The report provides separate ... Europe , Asia-Pacific , ... for the period 2012 through 2020. Market data and analytics ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
(Date:8/19/2014)...   Synthetic Biologics, Inc. (NYSE MKT: ... and drug programs targeting specific pathogens that cause ... novel C. difficile development program will ... Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September ... Synthetic Biologics, Senior Vice President, Research ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... March 11 earthquake and rolling blackouts that are severely ... internship program NanoJapan is scrambling to run its annual ... travel to Japan for lab internships, NanoJapan is offering ... students to Rice University laboratories for three months. ...
... 25, 2011 WaferGen Biosystems, Inc. (OTCBB:WGBS), a ... announced it has entered into definitive agreements with ... Partners, LLC, Deerfield Management and Merlin Nexus, and ... a $30.4 million private placement financing of equity ...
... Texas, May 25, 2011 /PRNewswire/ -- ... company, today announced that the United States Patent and Trademark ... patent entitled "Saposin D and Fam3C are Biomarkers for Alzheimer,s ... Fam3c as well as combinations that include these biomarkers. ...
Cached Biology Technology:Reverse NanoJapan: Rice to host 25-30 Japanese students 2WaferGen Announces $30 Million Financing 2WaferGen Announces $30 Million Financing 3WaferGen Announces $30 Million Financing 4Vermillion Announces Notice of Allowance for Alzheimer Patent 2Vermillion Announces Notice of Allowance for Alzheimer Patent 3
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
(Date:8/19/2014)... at retail seafood counters in 10 different states ... consumers to unexpectedly high levels of mercury, a ... a fish of the same species, but from ... offense, according to new research by University of ... seafood is essential to allow consumers to choose ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Evolution of marine crocodilians constrained by ocean temperatures 2
... methods and better testing systems are needed to advance ... to a series of review articles in Human ... Ann Liebert, Inc ( www.liebertpub.com ). The articles and ... www.liebertpub.com/hum Prostate cancer is one of the ...
... Oxford, 12 July 2010 - The British Mycological Society, ... technical and medical information, today announced the final programme ... Fungi. This congress takes place every 4 years at ... the Edinburgh International Conference Centre, a comprehensive programme encompasses ...
... with your chip shot? Constant drills with your wedge may ... a new study shows why. Previous studies have shown ... better than practice focused on a single task. Cognitive neuroscientists ... paradox in a new study in Nature Neuroscience . ...
Cached Biology News:Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy 2The biology of fungi -- 1.5 million species -- 1 congress 2Why (smart) practice makes perfect 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
QML offers standard and customized paraffin embedded tissue blocks....
Request Info...
Biology Products: